NCT00681187已完成4 期
A Phase IV, International, Open-label, Randomised, Cross-over Study to Assess Patient Preference and Health Economy in Patients With Neuroendocrine Tumours, Treated With Lanreotide Autogel Given as Self Administration.
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Ipsen
- 入组人数
- 26
- 试验地点
- 20
- 主要终点
- Subject Preference for Self or Partner Administration
研究概览
简要总结
The primary aim of this study is to assess which method of lanreotide Autogel administration patients with neuroendocrine tumours prefer - self/partner administrations or healthcare provided administrations. The study will also assess if self/partner administration can be performed without loss of efficacy and with a preserved safety profile. The impact of self/partner administration on resource utilisation and costs will be studied. In addition, we will also assess the healthcare provider's experience of the two administration practices.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of written informed consent from the patient and their partner (if the partner will be administering the lanreotide Autogel injections during the self administration period)
- •Male or female aged 18 years of age or older
- •Treated with lanreotide Autogel 90 or 120 mg every 28th day for carcinoid symptoms on a stable dose for at least 3 months prior to inclusion. The patient is presumed to be clinically stable during the coming months
- •Neuroendocrine tumour confirmed by biopsy and visible on radiology
排除标准
- •Has a history of hypersensitivity to the Investigational Medicinal Product or drugs with a similar chemical structure
- •Has abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardise the patient's safety or decrease the chance of obtaining satisfactory data needed to achieve the objective(s) of the study
- •Has a life expectancy less than a year, as judged by the Investigator
- •The patient or their partner is not considered competent in injection technique, as judged by the Investigator
结局指标
主要结局
Subject Preference for Self or Partner Administration
时间窗: Between week 30 to 34
A global question was asked: 'If you could choose, which administration method would you like to use on a regular basis?' A) Healthcare professional provided injection B) Self/ partner administered injection
次要结局
- Number of Patients Stating at Least One Injection Interfered With Daily Activities(Between baseline to week 32, after each injection (8-9 injections))
- Number of Patients Stating at Least One Injection Negatively Interfered With Psychological Wellbeing(Between baseline to week 32, after each injection (8-9 injections))
- Days Sick Leave(Group 1 - between week 8 to 20 (self or partner administration), between week 20 to 32 (HCP administration). Group 2 - between week 20 to 32 (self or partner administration), between week 0 to week 12 (HCP administration))
- Total Number of Visits to HCP Due to Carcinoid Symptoms(Group 1 - between week 8 to 20 (self or partner administration), between week 20 to 32 (HCP administration). Group 2 - between week 20 to 32 (self or partner administration), between week 0 to week 12 (HCP administration))
- Perceived Symptom Control Evaluation in Respect to Episodes of Flushing(Group 1 - baseline, week 16 to 20 (self or partner administration) and week 30 to 34 (HCP administration). Group 2 - baseline, week 12 (HCP administration) and week 30 (self or partner administration).)
- Perceived Symptom Control Evaluation in Respect to Episodes of Diarrhoea(Group 1 - baseline, week 16 to 20 (self or partner administration) and week 30 to 34 (HCP administration). Group 2 - baseline, week 12 to 16 (HCP administration) and week 30 to 34 (self or partner administration).)
- Chromogranin A Levels(Group 1 - Baseline, week 16 to 20 and 30 to 34. Group 2 - Baseline, week 12 and 30 to 34.)
- 5-hydroxyindoleacetic Acid (5-HIAA) Levels(Group 1 - Baseline, week 16 to 20 and 30 to 34. Group 2 - Baseline, week 12 and 30 to 34.)
- Healthcare Professionals With Positive Response to Specified Questions on Self or Partner Administration Method(Between week 30 to 34)
研究者
研究点 (20)
Loading locations...
相似试验
已完成
3 期
Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsGastroenteropancreatic Neuroendocrine TumorNCT04852679Ipsen43
已完成
3 期
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic PatientsAcromegalyNCT00383708Ipsen125
已完成
2 期
Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver DiseasePolycystic Liver DiseaseNCT01315795Universitaire Ziekenhuizen KU Leuven59
已完成
3 期
Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in AcromegalyAcromegalyNCT02493517Ipsen128
已完成
3 期
Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With AcromegalyAcromegalyNCT00499993Ipsen63